Teva Pharma

Jump to

Hope to commercialise 4 products acquired from Teva by FY18: DRL

Saumen Chakraborty, CFO of the company told CNBC-TV18 that they hope to commercialise four out of the eight products by FY18. He said all the eight products are expected to have limited competition.
Dr Reddy's up; analysts say Teva deal to reflect in 2018 revenue

The portfolio being acquired for USD 350 million is a mix of filed ANDAs pending approval and an approved ANDA, and comprised of complex generic products across diverse dosage forms.
US Supreme Court rules for Teva over MS drug patent

US supreme court has suggested that Appeals court did not use the right approach in analyzing whether Teva's September 2015 patent is valid or not.
Teva will get part of profit from Lipitor sale by Ranbaxy

Industry sources tell PharmAsia News that Ranbaxy forged the Teva Lipitor deal as a back-up plan to try and ensure an on-time launch.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347

Teva Pharma

Hope to commercialise 4 products acquired from Teva by FY18: DRL

Dr Reddy's up; analysts say Teva deal to reflect in 2018 revenue

US Supreme Court rules for Teva over MS drug patent

Teva will get part of profit from Lipitor sale by Ranbaxy